Skip to main content
. 2021 Dec 22;23(1):73. doi: 10.3390/ijms23010073

Figure 5.

Figure 5

Significant differences in the mRNA levels of (A) CPS1 and (B) TRIP6 genes and (C) CPS1 and TRIP6 proteins in ovarian carcinoma mouse xenografts after the treatment with paclitaxel and novel SB-Ts in vivo. (A,B) Gene expression differences are shown as a mean of fold change (2−∆∆CT) ± SD, between the control group (Group I), group treated with 10 mg/kg paclitaxel (Group II), 9 mg/kg paclitaxel + 1 mg/kg SB-T-121605 (Group III), 7 mg/kg paclitaxel + 3 mg/kg SB-T-121605 (Group IV), 9 mg/kg paclitaxel + 1 mg/kg SB-T-121606 (Group V), and 7 mg/kg paclitaxel + 3 mg/kg SB-T-121606 (Group VI). Statistical analysis was performed by the two-tailed Student´s t-test * p < 0.05, ** p < 0.01, *** p < 0.001). (C) Representative immunoblot of CPS1, TRIP6, and β-ACTIN proteins in each group of mouse xenografts. Each group consisted of five mice.